"Anti-Ulcer Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief.
| Descriptor ID |
D000897
|
| MeSH Number(s) |
D27.505.954.483.203
|
| Concept/Terms |
Anti-Ulcer Agents- Anti-Ulcer Agents
- Agents, Anti-Ulcer
- Anti Ulcer Agents
- Anti-Ulcer Drugs
- Anti Ulcer Drugs
- Drugs, Anti-Ulcer
|
Below are MeSH descriptors whose meaning is more general than "Anti-Ulcer Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Ulcer Agents".
This graph shows the total number of publications written about "Anti-Ulcer Agents" by people in this website by year, and whether "Anti-Ulcer Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 6 | 5 | 11 |
| 1997 | 5 | 1 | 6 |
| 1998 | 1 | 3 | 4 |
| 1999 | 3 | 5 | 8 |
| 2000 | 2 | 2 | 4 |
| 2001 | 4 | 0 | 4 |
| 2002 | 4 | 2 | 6 |
| 2003 | 8 | 2 | 10 |
| 2004 | 1 | 3 | 4 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 2 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 2 | 4 |
| 2010 | 3 | 0 | 3 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 2 | 1 | 3 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 2 | 3 |
| 2019 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Ulcer Agents" by people in Profiles.
-
Sucralfate as an Adjunct to Analgesia to Improve Oral Intake in Children With Infectious Oral Ulcers: A Randomized, Double-Blind, Placebo-Controlled Trial. Ann Emerg Med. 2021 09; 78(3):331-339.
-
Management of gastroesophageal reflux disease. Dis Mon. 2020 Jan; 66(1):100849.
-
Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter. 2019 Feb; 24(1):e12554.
-
Helicobacter pylori eradication: influence of interleukin-1beta -31 C/T polymorphism. Braz J Infect Dis. 2018 Jul - Aug; 22(4):311-316.
-
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther. 2018 06; 47(11):1453-1463.
-
Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran. Dig Dis Sci. 2017 08; 62(8):1890-1896.
-
Helicobacter pylori eradication in the Swedish population. Scand J Gastroenterol. 2017 Jun - Jul; 52(6-7):678-685.
-
Acute Erosive Esophagitis As a Rare Complication of Severe Pediatric Diabetes Ketoacidosis. J Pediatr Gastroenterol Nutr. 2016 Apr; 62(4):e38-9.
-
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. Leuk Lymphoma. 2016 08; 57(8):1800-6.
-
Omeprazole Attenuates Pulmonary Aryl Hydrocarbon Receptor Activation and Potentiates Hyperoxia-Induced Developmental Lung Injury in Newborn Mice. Toxicol Sci. 2015 Nov; 148(1):276-87.